Global Health & Biotech Archives | Page 97 of 292 | Be Korea-savvy

Archive by category Global Health & Biotech

Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate

Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate

  Enters into a commercialization agreement for SB17, ustekinumab biosimilar candidate, in Europe and North America Partnership to support Samsung Bioepis pipeline expansion and provide increased access to biosimilars INCHEON, Korea, Sept. 11, 2023 (Korea Bizwire) – Samsung Bioepis Co., Ltd. today announced that it has entered into a commercialization agreement with Sandoz for SB17, [...]

Novotech Releases Comprehensive Global Landscape Report on Gallbladder Cancer Clinical Trials

Novotech Releases Comprehensive Global Landscape Report on Gallbladder Cancer Clinical Trials

BOSTON, Sept. 7 (Korea Bizwire) – Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today published the latest specialist clinical trial report –“Gallbladder Cancer: Global Clinical Trials Landscape Report”. According to the report, biopharma companies have initiated approximately 250 ongoing clinical trials in gallbladder cancer (GBC) since 2016, with the Asia-Pacific region [...]

Novotech Publishes Nasopharyngeal Carcinoma Global Clinical Trial Landscape Report

Novotech Publishes Nasopharyngeal Carcinoma Global Clinical Trial Landscape Report

BOSTON, Sept. 7 (Korea Bizwire) – Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today published the latest specialist clinical trial report – “Nasopharyngeal Carcinoma: Global Clinical Trial Landscape”. According to the report, since 2018, the biopharma industry has initiated over 200 global clinical trials for nasopharyngeal carcinoma (NPC), with 60% of these [...]

Philips Reaches Resolution of US Economic Loss Litigation

Philips Reaches Resolution of US Economic Loss Litigation

Amsterdam, the Netherlands, Sept. 7 (Korea Bizwire) – Royal Philips (NYSE: PHG, AEX: PHIA) announced today that the company and certain of its US subsidiaries, including Philips Respironics, have reached an agreement to resolve all economic loss claims in the US Multidistrict Litigation (MDL) related to Philips Respironics’ voluntary recall of certain sleep and respiratory care devices. This settlement, [...]

BVI Significantly Expands Its Presence in Spain and Portugal Acquiring Medical Mix

BVI Significantly Expands Its Presence in Spain and Portugal Acquiring Medical Mix

WALTHAM, Mass., Sept. 6 (Korea Bizwire) — BVI, one of the fastest-growing, diversified surgical ophthalmic businesses in the world, announced the acquisition of Medical Mix, a company specializing in the supply of medical devices for ophthalmic surgery across Spain and Portugal. This strategic move builds on a period of significant momentum for BVI. The company [...]

Nyxoah to Participate in Upcoming Investor Conferences

Nyxoah to Participate in Upcoming Investor Conferences

Mont-Saint-Guibert, Belgium, Sept. 5 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in two upcoming investor conferences in New York City. Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver [...]

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia

WALTHAM, Mass., Sept. 5 (Korea Bizwire) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies, today announced that it has entered into a license and collaboration agreement with Bristol Myers Squibb Company to develop and commercialize obexelimab for autoimmune diseases in Japan, South Korea, [...]

Sabin Vaccine Institute Leads Public and Private Sector Fight to Prevent HPV and End Cervical Cancer with Global HPV Consortium Launch in Kuala Lumpur

Sabin Vaccine Institute Leads Public and Private Sector Fight to Prevent HPV and End Cervical Cancer with Global HPV Consortium Launch in Kuala Lumpur

KUALA LUMPUR, Malaysia, Sept. 5 (Korea Bizwire) — The Global HPV Consortium, a worldwide public and private collaboration focused on accelerating prevention of Human Papillomavirus (HPV) and eliminating cervical cancer, launched today in Kuala Lumpur, Malaysia. The Sabin Vaccine Institute will lead the Consortium as its Secretariat. “We are building a new ecosystem in global [...]

Junshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates

Junshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates

SHANGHAI, China, Aug. 30 (Korea Bizwire) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2023 interim financial results and provided corporate updates. FINANCIAL HIGHLIGHTS As of 30 June 2023, the company’s total revenue was [...]

Information on the Total Number of Voting Rights and Shares

Information on the Total Number of Voting Rights and Shares

Mont-Saint-Guibert (Belgium), Aug. 30 (Korea Bizwire) – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 4,925,869.05 Total number of securities carrying voting rights: 28,673,985 (all ordinary shares) Total number of [...]